2020
Anti-Müllerian hormone as a qualitative marker - or just quantity?
Kotlyar A, Seifer DB. Anti-Müllerian hormone as a qualitative marker - or just quantity? Current Opinion In Obstetrics & Gynecology 2020, 32: 219-226. PMID: 32205525, DOI: 10.1097/gco.0000000000000623.Peer-Reviewed Original ResearchConceptsAnti-Müllerian hormoneOvarian reserve testingClinical pregnancy rateLive birth rateOnset of menopausePremature ovarian insufficiencyNumber of oocytesSignificant predictive valueAMH levelsFertilization cyclesPregnancy rateOvarian insufficiencyIntracycle variabilityOocyte qualityPredictive valueEarly folliclesFetal trisomiesHormoneReproductive technologiesRiskQualitative markersSmall interMenopauseInsufficiencyFolliclesHigh serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology
Tal R, Seifer CM, Khanimov M, Seifer DB, Tal O. High serum Antimullerian hormone levels are associated with lower live birth rates in women with polycystic ovarian syndrome undergoing assisted reproductive technology. Reproductive Biology And Endocrinology 2020, 18: 20. PMID: 32156287, PMCID: PMC7065318, DOI: 10.1186/s12958-020-00581-4.Peer-Reviewed Original ResearchConceptsLive birth rateLower live birth ratesHigh AMH groupAMH groupPCOS womenHigh AMHAMH concentrationsFirst fresh IVF/ICSI cycleBirth rateFresh IVF/ICSI cyclesGreater clinical pregnancy ratesSerum antimullerian hormone (AMH) levelsIVF/ICSI cyclesAntimullerian hormone levelsClinical pregnancy rateControlled ovarian stimulationRetrospective cohort studySerum AMH levelsPolycystic ovarian syndromeSerum AMH concentrationsLive birth outcomesNumber of embryosAMH levelsGonadotropin doseOvarian stimulation
2014
Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis
Tal R, Tal O, Seifer BJ, Seifer DB. Antimüllerian hormone as predictor of implantation and clinical pregnancy after assisted conception: a systematic review and meta-analysis. Fertility And Sterility 2014, 103: 119-130.e3. PMID: 25450298, DOI: 10.1016/j.fertnstert.2014.09.041.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEmbryo ImplantationFemaleFertilization in VitroHumansInfertility, FemaleMiddle AgedObservational Studies as TopicOvarian ReserveOvaryOvulation InductionPregnancyPregnancy OutcomePregnancy RatePrevalenceReproducibility of ResultsRisk FactorsSensitivity and SpecificityYoung AdultConceptsPredictor of implantationClinical pregnancy rateAntimüllerian hormoneClinical pregnancyOvarian reservePregnancy rateOdds ratioIVF/intracytoplasmic sperm injectionSystematic reviewSerum AMH levelsPolycystic ovary syndromeReproductive technologiesIntracytoplasmic sperm injectionNondonor cyclesAMH levelsOvary syndromeImplantation rateDiagnostic odds ratioObservational studyMAIN OUTCOMEClinical utilitySperm injectionPregnancyAssisted conceptionFertility treatmentAssisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011
Butts SF, Owen C, Mainigi M, Senapati S, Seifer DB, Dokras A. Assisted hatching and intracytoplasmic sperm injection are not associated with improved outcomes in assisted reproduction cycles for diminished ovarian reserve: an analysis of cycles in the United States from 2004 to 2011. Fertility And Sterility 2014, 102: 1041-1047.e1. PMID: 25086790, PMCID: PMC4184996, DOI: 10.1016/j.fertnstert.2014.06.043.Peer-Reviewed Original ResearchMeSH KeywordsChi-Square DistributionEmbryo Culture TechniquesEmbryo TransferFemaleHumansInfertility, FemaleLive BirthLogistic ModelsOdds RatioOvarian ReservePregnancyPregnancy RatePrimary Ovarian InsufficiencyRegistriesRetrospective StudiesRisk FactorsSperm Injections, IntracytoplasmicTime FactorsTreatment OutcomeUnited StatesConceptsDiminished ovarian reserveIntracytoplasmic sperm injectionElevated FSHLive birthsOvarian reserveART cyclesSperm injectionAssisted Reproductive Technology Clinic Outcome Reporting System databaseClinical pregnancy rateRetrospective cohort studyLive birth rateReproductive technology outcomesAssisted reproduction cyclesCombination of ICSIReporting System databaseCohort studyPrimary diagnosisImproved outcomesPregnancy rateMAIN OUTCOMELower oddsDiminished oddsFSHOnly indicationTechnology outcomesCharacterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes
Tal R, Seifer DB, Khanimov M, Malter HE, Grazi RV, Leader B. Characterization of women with elevated antimüllerian hormone levels (AMH): correlation of AMH with polycystic ovarian syndrome phenotypes and assisted reproductive technology outcomes. American Journal Of Obstetrics And Gynecology 2014, 211: 59.e1-59.e8. PMID: 24593938, DOI: 10.1016/j.ajog.2014.02.026.Peer-Reviewed Original ResearchConceptsSerum antimüllerian hormone levelsAntimüllerian hormone levelsClinical pregnancy ratePopulation of womenAMH levelsPregnancy rateHormone levelsHigher clinical pregnancy rateElevated AMH levelsPresence of amenorrheaMultiple pregnancy rateOvarian hyperstimulation syndromeRetrospective cohort studyHigher AMH levelsPolycystic ovarian morphologyPolycystic ovarian syndromeSyndrome phenotypeReproductive technology outcomesHyperstimulation syndromePCOS severityClinical pregnancyOvarian stimulationTotal testosteroneCohort studyOvarian syndrome
2011
Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels
Buyuk E, Seifer DB, Younger J, Grazi RV, Lieman H. Random anti-Müllerian hormone (AMH) is a predictor of ovarian response in women with elevated baseline early follicular follicle-stimulating hormone levels. Fertility And Sterility 2011, 95: 2369-2372. PMID: 21497340, DOI: 10.1016/j.fertnstert.2011.03.071.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersChi-Square DistributionEmbryo TransferFemaleFertilization in VitroFollicle Stimulating Hormone, HumanFollicular PhaseHumansInfertility, FemaleNew YorkOocyte RetrievalOvulationOvulation InductionPregnancyPregnancy RateRetrospective StudiesTime FactorsTreatment OutcomeUp-RegulationConceptsAnti-Müllerian hormoneNumber of oocytesClinical pregnancy rateSerum AMH levelsDiminished ovarian reserveAMH levelsFSH levelsDay 3 embryosElevated FSHOvarian responseART cyclesPregnancy rateEarly follicular FSH levelsFollicle-stimulating hormone levelsSerum anti-Müllerian hormoneCycle cancellation rateSerum FSH levelsReproductive technology programCycle cancellationOvarian reserveRetrospective studyHormone levelsMAIN OUTCOMECancellation rateRandom sera
2005
Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology
Silberstein T, MacLaughlin DT, Shai I, Trimarchi JR, Lambert-Messerlian G, Seifer DB, Keefe DL, Blazar AS. Müllerian inhibiting substance levels at the time of HCG administration in IVF cycles predict both ovarian reserve and embryo morphology. Human Reproduction 2005, 21: 159-163. PMID: 16123085, DOI: 10.1093/humrep/dei270.Peer-Reviewed Original ResearchConceptsBasal FSH levelsOvarian reserveFSH levelsHCG administrationMIS levelsIVF outcomesOocyte qualityDay 3 FSH levelsMI levelsImproved oocyte qualityTime of hCGClinical pregnancy rateManagement of patientsSerum estradiol levelsHigher implantation rateEmbryo morphologyEmbryo morphology scoreNumber of oocytesEarly antral folliclesEnzyme-linked immunosorbentIVF cyclesOocyte retrievalPatient ageEstradiol levelsImplantation rate
2004
Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol
Hazout A, Bouchard P, Seifer DB, Aussage P, Junca AM, Cohen-Bacrie P. Serum antimüllerian hormone/müllerian-inhibiting substance appears to be a more discriminatory marker of assisted reproductive technology outcome than follicle-stimulating hormone, inhibin B, or estradiol. Fertility And Sterility 2004, 82: 1323-1329. PMID: 15533354, DOI: 10.1016/j.fertnstert.2004.03.061.Peer-Reviewed Original ResearchMeSH KeywordsAdultAnti-Mullerian HormoneBiomarkersEstradiolFemaleFertilization in VitroFollicle Stimulating HormoneGlycoproteinsHumansInhibinsMultivariate AnalysisOsmolar ConcentrationOvulation InductionPredictive Value of TestsPregnancyPregnancy RateRetrospective StudiesTesticular HormonesTime FactorsTreatment OutcomeConceptsReproductive technology outcomesMullerian-inhibiting substanceYears of ageMultivariate regression analysisInhibin BPregnancy outcomesIVF outcomesAntimullerian hormoneHigher clinical pregnancy rateSerum samplesAvailable serum markersDay 3 FSHSerum antimullerian hormoneClinical pregnancy rateClinical pregnancy outcomesInhibin B levelsFollicle-stimulating hormoneConsecutive serum samplesMüllerian-inhibiting substanceGreater prognostic valueTechnology outcomesRegression analysisClinical pregnancyOvarian stimulationOvulation induction
1999
Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone
Seifer D, Scott R, Bergh P, Abrogast L, Friedman C, Mack C, Danforth D. Women with declining ovarian reserve may demonstrate a decrease in day 3 serum inhibin B before a rise in day 3 follicle-stimulating hormone. Fertility And Sterility 1999, 72: 63-65. PMID: 10428149, DOI: 10.1016/s0015-0282(99)00193-4.Peer-Reviewed Original ResearchConceptsSerum inhibin B levelsInhibin B levelsDay 3 FSH levelsCycle cancellation rateClinical pregnancy rateSerum inhibin BOvarian reserveFSH levelsB levelsInhibin BPregnancy rateCancellation rateDay 3 follicle-stimulating hormoneDay 3 serum FSH levelsHigher cycle cancellation rateTertiary-care fertility centreNumber of ampulesSerum FSH levelsSerum FSH concentrationsFollicle-stimulating hormoneCase-control studyNumber of oocytesOvarian responsivenessFSH concentrationsGonadotropin requirements
1998
Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential
Friedman C, Seifer D, Kennard E, Arbogast L, Alak B, Danforth D. Elevated level of follicular fluid vascular endothelial growth factor is a marker of diminished pregnancy potential. Fertility And Sterility 1998, 70: 836-839. PMID: 9806563, DOI: 10.1016/s0015-0282(98)00301-x.Peer-Reviewed Original ResearchConceptsFF VEGF concentrationsAmpules of gonadotropinsVEGF concentrationsClinical pregnancyChart reviewFollicular fluid vascular endothelial growth factorFollicular fluid vascular endothelial growth factor concentrationsDay 3 FSH levelsFollicular fluid VEGF concentrationsVascular endothelial growth factor concentrationsClinical pregnancy rateEstradiol serum concentrationsPeak estradiol levelsRetrospective chart reviewUniversity teaching centerVascular endothelial growth factorNumber of oocytesYears of ageEndothelial growth factorGrowth factor concentrationsFF VEGFSingle IVFFSH levelsPatient ageEstradiol levels
1997
Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome
Seifer D, Lambert-Messerlian G, Hogan J, Gárdiner A, Blazar A, Berk C. Day 3 serum inhibin-B is predictive of assisted reproductive technologies outcome. Fertility And Sterility 1997, 67: 110-114. PMID: 8986693, DOI: 10.1016/s0015-0282(97)81865-1.Peer-Reviewed Original ResearchConceptsClinical pregnancy rateNumber of oocytesSerum inhibin B concentrationPg/mLInhibin B concentrationsSerum inhibinPregnancy ratePg/Clinical pregnancyOvulation inductionSerum E2Poor responseCancellation rateDay 3 serum FSHAssisted reproductive technology cyclesGnRH agonist suppressionInhibin B valuesReproductive technology cyclesDay of hCGSpontaneous abortion rateAcademic clinical practiceReproductive technologiesSerum FSHOdds ratioE2 response
1995
Laparoscopic-assisted tubal anastomosis
Frishman G, Seifer D. Laparoscopic-assisted tubal anastomosis. Journal Of Minimally Invasive Gynecology 1995, 2: 411-415. PMID: 9050594, DOI: 10.1016/s1074-3804(05)80062-3.Peer-Reviewed Original ResearchConceptsTubal anastomosisHospital stayPregnancy rateLower body mass indexPostoperative pregnancy rateClinical pregnancy rateTertiary care settingBody mass indexLength of procedureLong-term resultsLaparoscopic approachMass indexPatent tubesSame surgeonTubal ligationTubal segmentsCare settingsLaparotomyLarger studyPatientsAnastomosisLatter groupSimilar time periodWomenLaparoscopic
1994
Reproductive potential after treatment for persistent ectopic pregnancy **Presented in part at the conjoint meeting of The American Fertility Society and the Canadian Fertility and Andrology Society, Montreal, Quebec, Canada, October 11 to 14, 1993.
Seifer D, Silva P, Grainger D, Barber S, Grant W, Gutmann J. Reproductive potential after treatment for persistent ectopic pregnancy **Presented in part at the conjoint meeting of The American Fertility Society and the Canadian Fertility and Andrology Society, Montreal, Quebec, Canada, October 11 to 14, 1993. Fertility And Sterility 1994, 62: 194-196. PMID: 8005291, DOI: 10.1016/s0015-0282(16)56841-1.Peer-Reviewed Original ResearchConceptsContralateral fallopian tubeClinical pregnancy rateFallopian tubePregnancy rateCumulative clinical pregnancy rateIntrauterine pregnancy ratePersistent ectopic pregnancyAmerican Fertility SocietyClinical pregnancyEctopic pregnancyTreatment failureCanadian FertilityAndrology SocietySuccessful treatmentPrimary treatmentFertility SocietyRelative riskReproductive outcomesConjoint MeetingObvious pathologySignificant associationSuccess rateTreatmentPregnancySalpingectomy